SCHEMBL20920120

SCHEMBL20920120

COC(=O)c1nc2cc3c(-c4cc(C)nc(C)c4)nn(C(c4ccccc4)(c4ccccc4)c4ccccc4)c3cc2[nH]1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 3/20 0.35
KDM4E B2RXH2 4/20 0.34
FGFR1 P11362 1/20 0.34
FGFR2 P21802 1/20 0.34
SMN1; SMN2 Q16637 2/20 0.33
MAPT P10636 2/20 0.33
ADORA3 P0DMS8 1/20 0.33
RHEB Q15382 1/20 0.33
TNKS O95271 1/20 0.33
ALDH1A1 P00352 3/20 0.32
HPGD P15428 3/20 0.32
POLB P06746 2/20 0.32
HSD17B10 Q99714 2/20 0.32
LMNA P02545 2/20 0.32
NPC1 O15118 1/20 0.32
PKM P14618 1/20 0.32
NFKB1 P19838 1/20 0.32
RAB9A P51151 1/20 0.32
NFKB2 Q00653 1/20 0.32
RELA Q04206 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22284329 0.91 PDE10A (0.40) MAPK1
SCHEMBL28333301 0.91 PIN1 (0.40) MAPK1KDM4ERHEBALDH1A1PIN1
SCHEMBL20917255 0.89 RAF1 (0.41) MAPK1KDM4EFGFR1FGFR2SMN1; SMN2
SCHEMBL30554282 0.89 RAF1 (0.41) MAPK1KDM4EFGFR1FGFR2SMN1; SMN2
SCHEMBL22284293 0.87 GSK3B (0.35) MAPK1KDM4EFGFR1FGFR2SMN1; SMN2
SCHEMBL22284224 0.86 PDE10A (0.37) MAPK1KDM4EFGFR1FGFR2SMN1; SMN2
SCHEMBL20916785 0.84 MAPK1 (0.37) MAPK1KDM4EFGFR1FGFR2SMN1; SMN2
SCHEMBL22284435 0.83 DGAT1 (0.36) MAPK1FGFR1FGFR2RHEBTNKS
SCHEMBL20916965 0.82 PDE10A (0.42) MAPK1PIN1
SCHEMBL22361080 0.78 PIN1 (0.36) KDM4ESMN1; SMN2MAPTALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3699179-A1 PYRAZOLYL-CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (CN) 2020-08-26 EP disclosed
US-20200247815-A1 PYRAZOLYL-CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) 2020-08-06 US disclosed
WO-2019076336-A1 PYRAZOLYL-CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF 江苏豪森药业集团有限公司 2019-04-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200247815-A1 PYRAZOLYL-CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF MAPK1, MAPK11, MAPK14 MAPK1 1/4885KDM4E 3782/4885FGFR1 558/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.